Amyloidosis is a rare and potentially life-threatening condition characterized by the accumulation of abnormal protein deposits, known as amyloids, in various organs and tissues. These deposits interfere with the normal functioning of vital organs, leading to severe complications such as heart failure, kidney damage, and nerve dysfunction. The amyloidosis therapeutics market is expanding rapidly due to the increasing prevalence of amyloidosis and the growing awareness surrounding early diagnosis and treatment. The market is forecast to grow from US$ 5.17 billion in 2025 to US$ 8.20 billion by 2032, at a CAGR of 6.8%. This growth is fueled by advancements in diagnostic technologies, the development of targeted therapies, and the rising demand for personalized treatment plans.
The market is predominantly driven by several key factors, including the rising prevalence of amyloidosis, early disease detection, and the increasing availability of novel treatments. The market is segmented by treatment type, end-user, and region. Among these segments, chemotherapy is expected to dominate, particularly for AL amyloidosis, while hospitals and clinics will remain the largest end-users. North America is projected to lead the global market, followed by Europe and the Asia Pacific regions, driven by healthcare advancements, strong research investments, and improving diagnostic capabilities.
Key Highlights from the Report
• The global amyloidosis therapeutics market is expected to grow at a CAGR of 6.8% from 2025 to 2032.
• Chemotherapy is expected to hold approximately 33% of the market share in 2025.
• Hospitals and clinics are projected to dominate the market, accounting for 51% of the market share in 2025.
• North America is anticipated to hold a market share of approximately 47% in 2025.
• The home care segment is witnessing rapid growth, particularly in North America and Europe.
• AI-driven diagnostic technologies are expected to enhance early detection and treatment outcomes.
Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/35504
Market Segmentation
The amyloidosis therapeutics market is divided based on various factors, including product type, end-user, and geographical region. These segments offer valuable insights into the therapeutic landscape, highlighting key trends and driving forces that shape the market.
Product Type Segmentation
The market is mainly segmented into chemotherapy, immunosuppressive drugs, and emerging treatments such as gene-silencing therapies and monoclonal antibodies. Chemotherapy holds a dominant share of the market, particularly for treating AL amyloidosis, which involves the use of high-dose melphalan in combination with autologous stem cell transplant (ASCT). Other chemotherapy drugs, such as proteasome inhibitors (bortezomib) and immunomodulatory drugs (lenalidomide), have become common in frontline therapies.
Immunosuppressive drugs, particularly corticosteroids like dexamethasone, along with newer agents like lenalidomide and pomalidomide, are expected to be the fastest-growing segment over the forecast period. These drugs work by reducing inflammation and suppressing the abnormal plasma cell clones responsible for producing amyloid proteins. The immunosuppressive drug segment, supported by advancements in combination therapies, will likely continue its rapid growth trajectory.
End-User Segmentation
In terms of end-users, hospitals and clinics are expected to dominate the amyloidosis therapeutics market. This is due to the sophisticated diagnostic procedures and specialized treatment protocols required for amyloidosis care, including chemotherapy, stem cell transplants, and monoclonal antibody therapies. Hospitals also have access to the latest imaging techniques, such as echocardiography and cardiac MRI, which play a critical role in diagnosing cardiac amyloidosis (CA).
The home care segment is witnessing increasing adoption, especially in North America and Europe. With the rise of telemedicine, remote monitoring, and hospital-community collaborations, patients are able to manage their condition from the comfort of their homes, reducing the need for frequent hospital visits. This shift toward home care is driven by patient preferences for convenience and cost-effectiveness, particularly among aging populations.
Regional Insights
North America
North America is the largest and fastest-growing region in the amyloidosis therapeutics market, accounting for an estimated 47% of the market share by 2025. The region benefits from a robust healthcare system, increased disease awareness, and strong research investments. The U.S. market is expected to continue experiencing significant growth, driven by the approval of novel therapies such as Alnylam’s Amvuttra for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the integration of artificial intelligence (AI) for early diagnosis. AI tools, such as the EchoGo Amyloidosis system, are enhancing diagnostic accuracy and enabling clinicians to detect amyloidosis in its early stages, improving patient outcomes.
Canada is also witnessing a rise in amyloidosis treatment adoption, with initiatives like the Amyloidosis Program of Calgary (APC) providing a multidisciplinary care approach and patient education. The country’s investment in research and collaboration between hospitals and home care providers is helping improve patient access to care, particularly in remote regions.
Europe
Europe is another key market for amyloidosis therapeutics, driven by strong healthcare infrastructure and supportive regulatory frameworks. Major European countries, including Germany, France, the U.K., and Italy, contribute significantly to the growth of the market. The U.K. National Amyloidosis Centre, which tracks over 6,000 patients, has been instrumental in advancing amyloidosis care in the region.
Germany is expected to experience the highest growth in the amyloidosis therapeutics market within Europe, particularly for treating transthyretin amyloidosis (ATTR). The country has over 12 university hospitals focused on monitoring amyloidosis patients, which indicates a strong commitment to managing rare diseases. Moreover, Germany’s Federal Joint Committee (G-BA) ensures that effective treatments have the right industry access.
Asia Pacific
The Asia Pacific region is experiencing rapid growth in the amyloidosis therapeutics market due to expanding healthcare infrastructure, improved disease awareness, and government-backed initiatives. China and Japan are leading this growth. China’s recent inclusion of amyloidosis in its National Rare Disease List, along with faster approval pathways by the National Medical Products Administration (NMPA), has facilitated the adoption of new therapies. For instance, China recently approved Darzalex Faspro (daratumumab) for AL amyloidosis, expanding treatment options for patients in the country.
Japan has made significant strides in diagnostic techniques, including the widespread use of cardiac PYP scans, which have improved the detection and treatment of cardiac amyloidosis. Accelerated drug approvals for therapies like vutrisiran and acoramidis further contribute to market growth in the region.
Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/35504
Market Drivers
The amyloidosis therapeutics market is experiencing substantial growth due to several factors. One of the most significant drivers is the recent advancements in diagnostic technologies, which aid in early detection. Early diagnosis of amyloidosis is crucial for improving patient outcomes, as delayed recognition can lead to irreversible organ damage. Emerging imaging techniques, such as cardiac MRI and nuclear imaging, allow clinicians to detect amyloid deposits in affected organs more accurately. The integration of AI tools in diagnostic processes, such as deep learning algorithms applied to echocardiography and scintigraphy, has significantly enhanced early diagnosis.
Another key driver is the increasing prevalence of amyloidosis, particularly in aging populations. With the rising global incidence of diseases like chronic inflammatory conditions, which are often linked to secondary amyloidosis, there is a growing need for effective treatments. Furthermore, the approval of novel therapies for different subtypes of amyloidosis, such as tafamidis and vutrisiran for transthyretin amyloidosis, has expanded treatment options and improved patient prognosis.
Market Restraints
Despite the promising growth, the amyloidosis therapeutics market faces several challenges. One of the major restraints is the high cost of treatment. The price of disease-modifying therapies, particularly for transthyretin amyloidosis, can exceed US$ 200,000 annually per patient, making it financially inaccessible for many individuals, especially in countries with limited healthcare budgets. These high costs place a strain on both healthcare systems and patients, limiting access to life-saving treatments.
In addition, the complexity of diagnostic tests and treatment regimens for amyloidosis presents another challenge. The need for specialized equipment, such as cardiac MRI and biopsy procedures, adds to the overall cost and complexity of care. While advances in AI and remote monitoring tools offer potential solutions, the current infrastructure may not be universally accessible, particularly in low-income regions.
Market Opportunities
The amyloidosis therapeutics market presents several opportunities, particularly in the realm of innovative treatments. AI-driven diagnostic tools have the potential to revolutionize the way amyloidosis is detected and managed. With early diagnosis being critical to successful treatment outcomes, AI systems that can accurately analyze imaging data and identify high-risk patients will play a key role in improving prognosis and reducing mortality.
In addition, the increasing demand for personalized medicine offers significant opportunities for the development of targeted therapies. Researchers and pharmaceutical companies are increasingly focusing on creating drugs that target specific genetic mutations or protein deposits, offering more effective and tailored treatment options for amyloidosis patients.
Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/35504
Company Insights
Key players operating in the amyloidosis therapeutics market include:
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Company Limited
• Prothena Corporation
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• GSK plc
• Amgen Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Merck KGaA
• Sanofi
Recent Developments:
March 2025: Alnylam Pharmaceuticals announced the U.S. FDA approval of AMVUTTRA® (vutrisiran) for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
February 2025: The European Commission granted marketing authorization for acoramidis (Beyonttra™) for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Conclusion
The amyloidosis therapeutics market is poised for significant growth over the coming years, driven by advancements in diagnostic technologies, the increasing prevalence of amyloidosis, and the continuous development of novel therapies. While challenges remain, particularly regarding treatment costs and diagnostic complexities, opportunities for innovation, especially in AI-driven diagnostics and personalized medicine, hold great promise for improving patient outcomes. As key players continue to invest in research and development, the amyloidosis therapeutics landscape is set to evolve, offering hope to patients affected by this rare and debilitating condition.
